fairnymph
Ex-Bluelighter
Mon Aug 5, 5:41 PM ET
NEW YORK (Reuters Health) - The maker of the controversial painkiller OxyContin reported Monday that it has won two more lawsuits involving the drug.
OxyContin is designed to fight pain over a sustained period, but its time-release mechanism is foiled by abusers who crush the tablets and ingest, snort or inject the drug, resulting in a high similar to the one produced by heroin. In mid-April, the US Drug Enforcement Agency said that OxyContin may have contributed to more than 400 deaths over the past two years.
Subsequently, Purdue Pharma LP has been named in numerous lawsuits, which charge the privately held firm with failing to adequately warn consumers about OxyContin's potential for abuse or take other measures to prevent the illegal use of the drug.
According to Purdue Pharma, two such lawsuits filed in Kentucky and Ohio, respectively, were recently dismissed, bringing the total number of dismissals to 13.
A Purdue Pharma spokesman told Reuters Health that the company has not lost a single suit to date. "There have been no cases that have reached a conclusion at all, except for the dismissals."
"Purdue Pharma has not paid a penny in either settlements or damages to anyone," he added.
He said that there are currently about 120 other lawsuits over OxyContin pending against the company.
Despite its court victories, Purdue Pharma's image has suffered amid the fallout over the OxyContin deaths. In response to public pressure, the company is developing an abuse-resistant painkiller and is spearheading the establishment of a program to help fight drug abuse.
The program, called the Rx Action Alliance, is expected to bring together drugmakers, law enforcement agencies, healthcare groups and advocacy organizations to raise awareness about prescription drug abuse and diversion.
The spokesman said that the Rx Action Alliance is expected to be unveiled in the autumn. Previously, Stamford, Connecticut-based Purdue Pharma had said it was aiming to launch the program in June.
NEW YORK (Reuters Health) - The maker of the controversial painkiller OxyContin reported Monday that it has won two more lawsuits involving the drug.
OxyContin is designed to fight pain over a sustained period, but its time-release mechanism is foiled by abusers who crush the tablets and ingest, snort or inject the drug, resulting in a high similar to the one produced by heroin. In mid-April, the US Drug Enforcement Agency said that OxyContin may have contributed to more than 400 deaths over the past two years.
Subsequently, Purdue Pharma LP has been named in numerous lawsuits, which charge the privately held firm with failing to adequately warn consumers about OxyContin's potential for abuse or take other measures to prevent the illegal use of the drug.
According to Purdue Pharma, two such lawsuits filed in Kentucky and Ohio, respectively, were recently dismissed, bringing the total number of dismissals to 13.
A Purdue Pharma spokesman told Reuters Health that the company has not lost a single suit to date. "There have been no cases that have reached a conclusion at all, except for the dismissals."
"Purdue Pharma has not paid a penny in either settlements or damages to anyone," he added.
He said that there are currently about 120 other lawsuits over OxyContin pending against the company.
Despite its court victories, Purdue Pharma's image has suffered amid the fallout over the OxyContin deaths. In response to public pressure, the company is developing an abuse-resistant painkiller and is spearheading the establishment of a program to help fight drug abuse.
The program, called the Rx Action Alliance, is expected to bring together drugmakers, law enforcement agencies, healthcare groups and advocacy organizations to raise awareness about prescription drug abuse and diversion.
The spokesman said that the Rx Action Alliance is expected to be unveiled in the autumn. Previously, Stamford, Connecticut-based Purdue Pharma had said it was aiming to launch the program in June.
